US Biotech creates custom solutions in record time using OutSystems Platform

Redwood City, California - 27 March 2006

OutSystems announces that Tercica, a US based biopharmaceutical company, is using OutSystems Platform to create a set of systems that will support the company’s processes.

Tercica has recently completed all development stage phases and received approval from the Food and Drug Administration (FDA) for its new drug, Increlex ™. OutSystems Platform was used to create two systems, to ensure the company’s strategic go-to-market timing.

In two weeks, a Business Process Engine was built to automate and trace HR and Finance related processes. All actions taken by users are centrally registered and traceable. During the same time, and also with OutSystems Platform, Tercica created a system to manage the sales team interaction with the physicians’ community and the payers. This fully tailored CRM system was created in ten weeks, to support sales activities with physicians and insurance companies. The system offers both web and mobile interfaces (via Blackberry), allowing access to the sales force anywhere, anytime.

“After providing OutSystems with a set of requirements for our CRM system, they were able to build and demonstrate a working prototype within a few days. The ability to make changes quickly meant that we had the application in production in weeks rather than months. The end result is a fantastic product that meets our business needs, is extremely easy to use and that has been deployed rapidly to our sales force. We will definitely use OutSystems again,” says Bill Yates, Tercica’s Vice-President, IT.

Other company processes will be supported by these systems, allowing the full automation of Tercica’s daily activities and substantially reducing administrative overhead. “Since this project, we have deployed a number of other applications built with OutSystems technology, taking full advantage of its quick time-to-market.” – said Yates.

The agility provided by OutSystems Platform was fundamental for Tercica’s choice. “The OutSystems value proposition of Build Fast, Change Faster and Operate Cheaper resonates easily with today’s US enterprise, especially in fast growing industries like Biotech.” – says Paulo Rosado, CEO of OutSystems – “These organizations need tailored IT solutions that can be delivered in weeks and not in months or years. And they need the assurance that these solutions are flexible enough to quickly accommodate the evolution of the business.”


About Tercica

Tercica, Inc. is a biopharmaceutical company focused on the development and commercialization of products to improve endocrine health. The company's first product, Increlex(TM) (mecasermin (rDNA origin) injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the long-term treatment of severe Primary IGFD. For further information on Tercica, please visit

contact pricing